Literature DB >> 9449287

Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.

P M Roblin1, M R Hammerschlag.   

Abstract

Chlamydia pneumoniae was eradicated from the nasopharynges of 26 of 33 (78.8%) evaluable children and adults with community-acquired pneumonia who were treated with azithromycin. We tested 55 isolates of C. pneumoniae obtained from 46 of these patients against azithromycin. The MIC at which 90% of the isolates were inhibited and the minimal chlamydiacidal concentration at which 90% of strains tested were killed of azithromycin for these isolates were both 0.5 microg/ml. Seven patients remained culture positive after treatment. The MICs of azithromycin for isolates from two patients increased fourfold after therapy. However, all the patients with persistent infection improved clinically. Further studies of treatment of C. pneumoniae infection, utilizing culture, are needed both to assess efficacy and to monitor for the possible development of antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9449287      PMCID: PMC105482     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics.

Authors:  R B Jones; B Van der Pol; D H Martin; M K Shepard
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

2.  A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia.

Authors:  G Anderson; T S Esmonde; S Coles; J Macklin; C Carnegie
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

3.  Persistent infection with Chlamydia pneumoniae following acute respiratory illness.

Authors:  M R Hammerschlag; K Chirgwin; P M Roblin; M Gelling; W Dumornay; L Mandel; P Smith; J Schachter
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079

4.  Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia.

Authors:  S Schönwald; V Skerk; I Petricevic; V Car; L Majerus-Misic; M Gunjaca
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 5.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

6.  Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections.

Authors:  J J Roord; B H Wolf; M M Gossens; J L Kimpen
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

7.  Relative resistance to erythromycin in Chlamydia trachomatis.

Authors:  A Mourad; R L Sweet; N Sugg; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

8.  Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia.

Authors:  P M Roblin; G Montalban; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

9.  In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; K K Qumei; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group.

Authors:  S M Chien; P Pichotta; N Siepman; C K Chan
Journal:  Chest       Date:  1993-03       Impact factor: 9.410

View more
  23 in total

1.  Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Authors:  M R Hammerschlag; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 2.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

3.  The Role of Chlamydia in Upper Respiratory Tract Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.725

4.  Chlamydia pneumoniae resists antibiotics in lymphocytes.

Authors:  Hiroyuki Yamaguchi; Herman Friedman; Mayumi Yamamoto; Keigo Yasuda; Yoshimasa Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

5.  Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.

Authors:  Paul F Riska; Andrei Kutlin; Patrick Ajiboye; Arnold Cua; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 6.  Antibiotic resistance in Chlamydiae.

Authors:  Kelsi M Sandoz; Daniel D Rockey
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

Review 7.  Review of macrolides and ketolides: focus on respiratory tract infections.

Authors:  G G Zhanel; M Dueck; D J Hoban; L M Vercaigne; J M Embil; A S Gin; J A Karlowsky
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.

Authors:  Patricia M Roblin; Stephan A Kohlhoff; Charles Parker; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

9.  Current knowledge of Chlamydia pneumoniae and atherosclerosis.

Authors:  M R Hammerschlag
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

10.  In Vitro Activity of Levonadifloxacin (WCK 771) against Chlamydia pneumoniae.

Authors:  Stephan Kohlhoff; Natalia Huerta; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.